WuXi Biologics (Cayman) Inc. (BKK:WUXI06)
Thailand · Delayed Price · Currency is THB | Market Cap | 781.95B +52.6% |
| Revenue (ttm) | 98.25B +16.7% |
| Net Income | 22.13B +46.3% |
| EPS | 5.23 +47.9% |
| Shares Out | n/a |
| PE Ratio | 35.33 |
| Forward PE | 25.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,305 |
| Open | 4.840 |
| Previous Close | 4.840 |
| Day's Range | 4.740 - 4.840 |
| 52-Week Range | 3.020 - 4.980 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 25, 2026 |
About WuXi Biologics
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and ... [Read more]
Financial Performance
In 2025, WuXi Biologics's revenue was 21.79 billion, an increase of 16.68% compared to the previous year's 18.68 billion. Earnings were 4.91 billion, an increase of 46.25%.
Financial numbers in CNY Financial StatementsNews
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
SHANGHAI, July 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in ...
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in Green...
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facili...
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Cent...
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site w...
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping ou...
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the ...
WuXi Biologics Transcript: Investor update
PatroLab and TrueSite technologies are driving automation and cost reductions, while project momentum remains strong with a 50% YoY increase and expanded capacity. Revenue growth guidance is reaffirmed at 13%-17% (16%-20% ex-FX), with manufacturing and biosimilar segments set for rapid expansion.
WuXi Biologics Slides: Investor update
WuXi Biologics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP...
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued...
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing governance transparency and effectiveness to create...
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completi...
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing...
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
SHANGHAI, April 17, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningst...
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's...
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biolo...
WuXi Biologics Earnings Call Transcript: H2 2025
Record 2025 results with double-digit revenue and profit growth, margin expansion, and strong global project wins. Guidance for 2026 is 13%-17% revenue growth, reflecting currency and macro uncertainties, with continued investment in technology and capacity.
WuXi Biologics Earnings release: H2 2025
WuXi Biologics released its H2 2025 earnings on March 25, 2026, summarizing the period's financial results.
WuXi Biologics Slides: H2 2025
WuXi Biologics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 25, 2026.
WuXi Biologics Annual report: H2 2025
WuXi Biologics has published its H2 2025 annual report on March 25, 2026.
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results ...
WuXi Biologics Reports Record 2025 Annual Results
Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increa...
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use ...
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six p...